Figure 1From: Pazopanib as first line treatment for solitary fibrous tumours: the Royal Marsden Hospital experience Progression free survival: median rate 4.7 months (95% CI 1.8 – 7.4); 6-month rate 44.9% (95% CI 17.7 – 69.0). Back to article page